Table 3.
Case-control univariate analysis of KLF1 mutations
| Patient characteristics | β0/β0, αα/αα, XmnI (−/−), rs766432 (AA or AC), rs9399137 (TT or CT)* | P† | OR (95% CI) | |
|---|---|---|---|---|
| KLF1μ/wt (case, n = 7) | KLF1wt/wt (control, n = 362) | |||
| Gender, n | 5:2 | 233:129 | 1.000 | |
| Males: females | ||||
| Age of onset (years), mean ± SD | 13.71 ± 10.03 | 5.88 ± 4.10 | .001 | |
| Hemoglobin (g/L), mean ± SD | 82.57 ± 7.81 | 66.33 ± 17.53 | .006 | |
| HbF (g/L), mean ± SD‡ | 39.58 ± 21.80 | 9.17 ± 11.05 | <.001 | |
| Requirement for systematic transfusion, n | 3:4 | 21:341 | .007 | 0.082 (0.017–0.391) |
| No:yes | ||||
| Category of anemia | 7:0 | 41:321 | <.001 | 0.009 (0.000–0.153) |
| TI: TM | ||||
*
Similar genetic variants between case group and control group: The impact of 5 major genetic modifiers of β-thalassemia analyzed under Cox proportional hazards model was excluded from univariate analysis of KLF1 mutations.
†
P value was determined using either a Mann-Whitney U test or χ2 test as appropriate.
‡
HbF (g/L) was calculated from total Hb level and HbF (%).